Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;51(12):4370-4394.
doi: 10.1007/s10803-021-05237-9. Epub 2021 Sep 7.

Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder

Erin Henneberry  1 , Martine Lamy  1   2 , Kelli C Dominick  1   2 , Craig A Erickson  3   4
Affiliations

Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder

Erin Henneberry et al. J Autism Dev Disord. 2021 Dec.

Abstract

Recent decades have been marked by a wave drug treatment research in autism spectrum disorder (ASD). This work has resulted in improved ability to treat commonly occurring behavioral challenges associated with ASD including most prominently irritability marked by aggression, self-injurious behavior, and severe tantrums. While treatment of interfering behavior has progressed in our field, there remain several areas of unmet medical need including most prominently a lack of any approved drug therapies for the core, defining symptoms of autism. We outline the progress to date in the field of autism drug treatment while taking a future look forward into how decades of work can inform better future steps in this field.

Keywords: Anti-psychotic; Autism; Autism spectrum disorder; Drug treatment; Irritability; Psychopharmacology.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. (RUPP), R. U. O. P. P. (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62(11), 1266–1274. https://doi.org/10.1001/archpsyc.62.11.1266 - DOI
    1. Adler, B. A., Wink, L. K., Early, M., Shaffer, R., Minshawi, N., McDougle, C. J., & Erickson, C. A. (2015). Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: A chart review study. Autism, 19(1), 102–106. https://doi.org/10.1177/1362361314524641 - DOI - PubMed
    1. Aman, M. G., Findling, R. L., Hardan, A. Y., Hendren, R. L., Melmed, R. D., Kehinde-Nelson, O., & Katz, E. (2017). Safety and efficacy of memantine in children with autism: Randomized, placebo-controlled study and open-label extension. Journal of Child and Adolescent Psychopharmacology, 27(5), 403–412. https://doi.org/10.1089/cap.2015.0146 - DOI - PubMed - PMC
    1. Anagnostou, E., Aman, M. G., Handen, B. L., Sanders, K. B., Shui, A., Hollway, J. A., & Veenstra-VanderWeele, J. (2016). Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: A randomized clinical trial. JAMA Psychiatry, 73(9), 928–937. https://doi.org/10.1001/jamapsychiatry.2016.1232 - DOI - PubMed
    1. Anagnostou, E., Soorya, L., Chaplin, W., Bartz, J., Halpern, D., Wasserman, S., & Hollander, E. (2012). Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: A randomized controlled trial. Molecular Autism, 3(1), 16. https://doi.org/10.1186/2040-2392-3-16 - DOI - PubMed - PMC

MeSH terms

Substances